<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80546">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826747</url>
  </required_header>
  <id_info>
    <org_study_id>S52775</org_study_id>
    <nct_id>NCT01826747</nct_id>
  </id_info>
  <brief_title>Intrauterine Insemination and Luteal Fase Support</brief_title>
  <official_title>Impact of Luteal Phase Support With Vaginal Progesterone on the Clinical Pregnancy Rate in Intrauterine Insemination Cycles Stimulated With Gonadotrophins: a Prospective Randomized Multicentre Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Belgium: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to test the hypothesis that luteal phase support with vaginal progesterone
      leads to a higher clinical pregnancy rate (primary outcome) and live birth rate (secondary
      outcome) when compared to no luteal phase support in a program of  intrauterine insemination
      after controlled ovarian stimulation with gonadotrophins. Additionally,  the length of the
      luteal phase will be recorded (secondary outcome) in order to detect luteal phase
      defects/insufficiencies in the absence of luteal phase suppletion as well as luteal phase
      prolongation in case of luteal phase support which may be a burden for the patients waiting
      for the outcome of the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>clinical pregnancy rate per IUI cycle</measure>
    <time_frame>by ultrasound at ± 5 to 6 weeks after IUI</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>live birth rate per IUI cycle</measure>
    <time_frame>40 weeks after IUI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crinone (progesterone 8%, vaginal application)</intervention_name>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with an indication for IUI:

          -  unexplained infertility

          -  mild male factor infertility

          -  minimal-mild endometriosis

        Women:

          -  first IUI cycle ever

          -  normal ovulatory cycles (26-32d)

          -  age&lt;43,BMI≤30

          -  presence of at least one patent tube on hysterosalpingography and/or laparoscopy

          -  normal uterine cavity (ultrasound, hysterosalpingography, or laparoscopy)

        Men: Total motile count ≥ 5 Million/ml after capacitation

        Exclusion Criteria:

          -  Patients with contra-indication for pregnancy , infertility or progesterone use.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>May 6, 2013</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrauterine insemination</keyword>
  <keyword>luteal phase</keyword>
  <keyword>gonadotrophins</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
